A5032988282- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
- Epigenetics and DNA Methylation
- Cancer-related molecular mechanisms research
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
- MicroRNA in disease regulation
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Molecular Biology Techniques and Applications
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Fibroblast Growth Factor Research
- Cancer Genomics and Diagnostics
- RNA Interference and Gene Delivery
- Estrogen and related hormone effects
- Carcinogens and Genotoxicity Assessment
- Radiopharmaceutical Chemistry and Applications
- Histone Deacetylase Inhibitors Research
- Environmental Toxicology and Ecotoxicology
- Hippo pathway signaling and YAP/TAZ
- Melanoma and MAPK Pathways
- Kruppel-like factors research
- Prostate Cancer Diagnosis and Treatment
- Immune cells in cancer
Indian Institute of Technology Kanpur
2016-2025
McGill University
2007-2022
Indian Institute of Technology Delhi
2022
Chhatrapati Shahu Ji Maharaj University
2018-2020
Molecular Oncology (United States)
2018-2019
University of Michigan
2008-2017
Michigan Center for Translational Pathology
2008-2017
University of Mysore
2017
Comprehensive Blood & Cancer Center
2013
Howard Hughes Medical Institute
2008-2013
Enhancer of zeste homolog 2 (EZH2) is a mammalian histone methyltransferase that contributes to the epigenetic silencing target genes and regulates survival metastasis cancer cells. EZH2 overexpressed in aggressive solid tumors by mechanisms remain unclear. Here we show expression function cell lines are inhibited microRNA-101 (miR-101). Analysis human prostate revealed miR-101 decreases during progression, paralleling an increase expression. One or both two genomic loci encoding were...
Abstract Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. After extending our assessment FGFR across multiple tumor cohorts, we additional fusions intact kinase domains in lung squamous cell bladder thyroid oral glioblastoma, head neck All fusion partners tested exhibit oligomerization capability, suggesting shared...
Metabolomic profiling of prostate cancer (PCa) progression identified markedly elevated levels sarcosine (N-methyl glycine) in metastatic PCa and modest but significant elevation the metabolite urine. Here, we examine role key enzymes associated with metabolism progression. Consistent our earlier report, were significantly urine sediments compared to controls, a area under receiver operating characteristic curve 0.71. In addition, expression biosynthetic enzyme, glycine N-methyltransferase...
Breast cancer patients have benefited from the use of targeted therapies directed at specific molecular alterations. To identify additional opportunities for therapy, we searched genes with marked overexpression in subsets tumors across a panel breast profiling studies comprising 3,200 microarray experiments. In addition to prioritizing ERBB2, found AGTR1, angiotensin II receptor type I, be markedly overexpressed 10-20% cases multiple independent patient cohorts. Validation experiments...
SPINK1 is a therapeutic target in subset of patients with + /ETS − prostate cancer.
Abstract Emergence of an aggressive androgen receptor (AR)-independent neuroendocrine prostate cancer (NEPC) after androgen-deprivation therapy (ADT) is well-known. Nevertheless, the majority advanced-stage patients, including those with SPINK1-positive subtype, are treated AR-antagonists. Here, we show AR and its corepressor, REST, function as transcriptional-repressors SPINK1 , AR-antagonists alleviate this repression leading to upregulation. Increased SOX2 expression during...
The mechanism of action DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-CdR), a potential anticancer agent is believed to be activated by the demethylation tumor suppressor genes. We tested here hypothesis that demethylating agents also demethylate and activate genes involved in invasion metastasis therefore might increase risk developing metastasis. effect 5-aza-CdR on noninvasive human breast cancer cells MCF-7 ZR-75-1 was evaluated cell proliferation, invasion, migration assay....
Using an integrative genomics approach called amplification breakpoint ranking and assembly analysis, we nominated KRAS as a gene fusion with the ubiquitin-conjugating enzyme UBE2L3 in DU145 cell line, originally derived from prostate cancer metastasis to brain. Interestingly, analysis of tissues revealed that 2 62 metastatic cancers harbored aberrations at locus. In cells, UBE2L3-KRAS produces protein, specific knockdown which attenuates invasion xenograft growth. Ectopic expression protein...
Androgen deprivation therapy (ADT) is the most preferred treatment for men with metastatic prostate cancer (PCa). However, disease eventually progresses and develops resistance to ADT in majority of patients, leading emergence castration-resistant (mCRPC). Here, we assessed artesunate (AS), an artemisinin derivative, its anticancer properties ability alleviate androgen receptor (AR) antagonists. We have shown AS combination bicalutamide (Bic) attenuates oncogenic castrate-resistant (PC3,...
Urokinase plasminogen activator receptor (uPAR) is a multidomain protein that plays important roles in the growth, invasion, and metastasis of number cancers. In present study, we examined effects administration monoclonal anti-uPAR antibody (ATN-658) on prostate cancer progression vitro vivo. We effect treatment ATN-658 human cell migration, proliferation, regulation intracellular signaling pathways. For vivo studies, PC-3 cells (1 x 106) were inoculated into right flank male Balb C nu/nu...
Transcriptional repressors and corepressors play a critical role in cellular homeostasis are frequently altered cancer. C-terminal binding protein 1 (CtBP1), transcriptional corepressor that regulates the expression of tumor suppressors genes involved cell death, is known to multiple cancers. In this study, we observed overexpression mislocalization CtBP1 metastatic prostate cancer demonstrated functional significance progression. Transient stable knockdown cells inhibited their...
Colorectal cancer (CRC) is the third most common in world, and second leading cause of deaths US. Although, anti-EGFR therapy commonly prescribed for CRC, patients harboring mutations KRAS or BRAF show poor treatment response, indicating an ardent demand new therapeutic targets discovery. SPINK1 (serine peptidase inhibitor, Kazal type 1) overexpression has been identified many cancers including colon, lung, breast prostate. Our study demonstrates functional significance CRC progression...
Serine peptidase inhibitor, Kazal type-1 (SPINK1) overexpression defines the second most recurrent and aggressive prostate cancer subtype. However, underlying molecular mechanism pathobiology of SPINK1 in remains largely unknown.miRNA prediction tools were employed to examine SPINK1-3'UTR for miRNA binding. Luciferase reporter assays performed confirm binding shortlisted miR-338-5p/miR-421. Furthermore, miR-338-5p/-421-overexpressing cells (SPINK1-positive) evaluated oncogenic properties...